Valitor has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacological properties..
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currently have three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 20, 2018 | Series A | $2.52M | 3 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Z-Gen Capital | — | Series A |
Phaenomena West Capital | — | Series A |
SVE Capital | — | Series A |